Markets:

Overview

News

Currencies

International

Treasuries

Zai Lab Limited - American Depositary Shares (NQ:ZLAB)

19.90 -0.03 (-0.15%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Zai Lab Limited - American Depositary Shares

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Earnings Preview For Zai Lab ↗

May 08, 2023

Via Benzinga

Zai Lab Announces Strategic Partnership and Global License Agreement with MediLink Therapeutics for a Next Generation Antibody-Drug Conjugate Program in Oncology

April 27, 2023

YL212 expands Zai Lab’s lung cancer franchise and enriches its global oncology pipeline with a potential first-in-class ADC

From Zai Lab Limited

Via GlobeNewswire

Zai Lab Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

April 26, 2023

From Zai Lab Limited

Via GlobeNewswire

Zai Lab to Announce First Quarter 2023 Financial Results and Corporate Updates on May 9, 2023

April 20, 2023

Company to Host Conference Call and Webcast on May 10, 2023, at 8:00 a.m. ET

From Zai Lab Limited

Via GlobeNewswire

FDA's AdComm Panel Favors Innoviva's Drug For Multidrug-Resistant Bacterial Infections ↗

April 18, 2023

Via Benzinga

Zai Lab to Highlight New Data from its Oncology Portfolio at 2023 AACR Annual Meeting

April 11, 2023

New translational and clinical biomarker data from Zai Lab’s global oncology program ZL-1211 will be featured in a poster presentation (Abstract presentation number: 4531)

From Zai Lab Limited

Via GlobeNewswire

1 Hot Growth Stock to Buy Hand Over Fist Before It Blasts Off ↗

March 26, 2023

This company plans to be profitable soon, and its revenue is already spiking.

Via The Motley Fool

Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia

March 20, 2023

From Zai Lab Limited

Via GlobeNewswire

2 Unmatched Stocks Wall Street Thinks Will Soar 152% or More in the Next 2 Years ↗

March 17, 2023

Biotechs are capable of making huge gains in short periods, and they often do.

Via The Motley Fool

Earnings Scheduled For March 1, 2023 ↗

March 01, 2023

Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million.

Via Benzinga

Zai Lab's Earnings: A Preview ↗

February 28, 2023

Via Benzinga

Silicon Valley Bank Collapse Might Have Limited Impact On Asia, But Confidence Seems Shaken ↗

March 13, 2023

Some Asian firms have disclosed cash deposits at troubled U.S. lender Silicon Valley Bank (NASDAQ: SIVB), known for its deep ties with the healthcare and tech sector. Most emphasized that the amounts...

Via Benzinga

2 Stocks That Could Rebound and Rise 30% or More in 2023 ↗

March 10, 2023

They're down, but they aren't yet out.

Via The Motley Fool

Why Shares of MacroGenics Jumped Thursday ↗

March 09, 2023

The company made a sale worth as much as $200 million for the royalty rights for its type-1 diabetes therapy.

Via The Motley Fool

2 Growth Stocks With Incredible Potential in the Next 5 Years ↗

March 06, 2023

Neither is profitable, but both could be on the verge of massive booms in revenue.

Via The Motley Fool

Veritone, Samsara, Lexicon Pharmaceuticals And Other Big Stocks Moving Higher On Friday ↗

March 03, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Friday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Why Puma Biotechnology Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

March 03, 2023

Gainers ObsEva SA (NASDAQ: OBSV) surged 86.6% to $0.1978 after dropping over 12% on Thursday. ObsEva recently announced strategic reorganization to consolidate operations in Switzerland.

Via Benzinga

Why Cano Health Shares Are Trading Lower By Around 23%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

March 02, 2023

Gainers Exela Technologies, Inc. (NASDAQ: XELA) shares surged 45% to $0.0701 after the company announced $51 million of new funding, amendment increases existing securitization facility to $185 million...

Via Benzinga

Zai Lab Announces Full-Year 2022 Financial Results and Recent Corporate Updates

March 01, 2023

From Zai Lab Limited

Via GlobeNewswire

Zai Lab Announces Participation in March Investor Conferences

February 28, 2023

From Zai Lab Limited

Via GlobeNewswire

Zai Lab to Present Two New Phase 3 Analyses for Niraparib in Ovarian Cancer at the 2023 ESMO Gynaecological Cancers Congress

February 22, 2023

From Zai Lab Limited

Via GlobeNewswire

3 More Mid-Cap Biotechs The Street Sees Doubling

February 22, 2023

According to Wall Street research groups, these three mid-cap biotechs have 2x potential. It’s for the investor to decide if the upside justifies the risk.

Via MarketBeat

Zai Lab Announces NDA Acceptance of Sulbactam-Durlobactam (SUL-DUR) for Infections Caused by Acinetobacter baumannii in China by the NMPA

February 22, 2023

From Zai Lab Limited

Via GlobeNewswire

Mixed Signals On Valentine's Day: How Stocks Are Reacting To January Inflation Data ↗

February 14, 2023

Inflation cooled slightly in January, but saw increases in some areas due to the impact of surging food, energy and shelter prices on consumers, the U.S Labor Department said Tuesday.

Via Benzinga

Zai Lab to Announce Full-Year Financial Results and Corporate Updates on March 1, 2023

February 09, 2023

Company to Host Conference Call and Webcast on March 2, 2023, at 8:00 a.m. ET

From Zai Lab Limited

Via GlobeNewswire

Zai Lab Announces Participation in February Investor Conferences

January 31, 2023

From Zai Lab Limited

Via GlobeNewswire

Zai Lab Announces NDA for Sulbactam-Durlobactam (SUL-DUR) Granted Priority Review by China’s NMPA

January 30, 2023

From Zai Lab Limited

Via GlobeNewswire

Zai Lab Announces Inclusion of QINLOCK® (ripretinib) and NUZYRA® (omadacycline) in China’s National Reimbursement Drug List

January 18, 2023

From Zai Lab Limited

Via GlobeNewswire

Zai Lab Appoints Michel Vounatsos To Its Board of Directors

January 09, 2023

From Zai Lab Limited

Via GlobeNewswire

Stock Market Mostly Higher Amid Jobs Report; Tesla Price Cuts, GE Spinoff In Focus: Weekly Review ↗

January 06, 2023

The major indexes rallied Friday on the jobs report and services data.

Via Investor's Business Daily

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Zai Lab Limited - American Depositary Shares (NQ:ZLAB)

All News about Zai Lab Limited - American Depositary Shares

Starting at $3.75/week.

Subscribe Today